Analyst Silvan Tuerkcan works at JMP and is focused on the Healthcare sector with 111 price targets and ratings documented since 2019 spanning on 13 stocks. Analyst's average stock valuation to be materialised ratio is 31.18% with an average time for price targets to be met of 27.42 days.
Most recent stock forecast was given on TSHA, Taysha Gene Therapies Inc. at 01-Feb-2023.
Silvan Tuerkcan best performing recommendations are on TPTX (TURNING POINT THERAPEUTICS, INC).
The best stock recommendation documented was for GBIO at 1/19/2023. The price target of $7 was fulfilled within 15 days with a profit of $2.39 (51.84%) receiving and performance score of 34.56.
Average potential price target upside
Analyst name
Rating
Current price target
Potential distance
Previous price target
Date
Price targets met ratio
Average potential upside
Average time for PT to be met
Performance score
Buy
24
$6.45 (36.75%)
25
18 days ago
0/8 (0%)
$8.29 (44.33%)
Buy
24
$6.45 (36.75%)
28
26 days ago
0/3 (0%)
$14.26 (72.40%)
Buy
32
$14.45 (82.34%)
35
1 months 28 days ago
0/8 (0%)
$15.52 (78.71%)
Buy
21
$3.45 (19.66%)
26
3 months 4 days ago
1/4 (25%)
$5.46 (30.05%)
172
Hold
22
$4.45 (25.36%)
23
3 months 4 days ago
6/11 (54.55%)
$2.26 (11.75%)
149
